11 news items
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
. Name and address of MA holder: Baxalta Innovations GmbH, Industriestrasse 67, A-1221 Vienna
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
AAN
AGRI
ALLG
17 Jun 24
for pulmonary arterial hypertension.
Kaival Brands Innovations Group, Inc
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
internal and external innovation to best serve patients."
As part of the agreement, Ascentage Pharma
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
.This innovative research collaboration has generated one of the largest cohort data sets globally of HAE
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness
6u03agwixip dfjazdznokfp5yo4464qc4p7pph7m3v31
TAK
16 May 24
, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative
xxz9elgbewt50cjc jrgnqj1t229j07koj49k5702twy34mou
SCLX
TAK
14 May 24
"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
m9h1qhuhbr879hugormzlms15cxwp8nmax8y6j5223zag web7e3kle7
ACIU
TAK
13 May 24
in the field of active immunotherapy, we are developing an innovative approach that could change the treatment paradigm for Alzheimer's disease
vl1 ifjj8run292y8mpgadywx5e95eszaaap
ACIU
TAK
13 May 24
.
"As pioneers in the field of active immunotherapy, we are developing an innovative approach that could change
x7tk4
TAK
9 May 24
approvals from the U.S. FDA in FY2023, Takeda's performance demonstrates the potential of our pipeline and our ability to bring our innovative medicines
wck1 imh4xz8kxpzhdrjyo
TAK
22 Apr 24
Japan and toward the creation of innovative therapeutics
- Prev
- 1
- Next